摘要
目的探讨中药联合肝动脉化学治疗栓塞术(TACE)治疗肝癌的临床效果。方法选取2013年12月至2018年12月北部战区总医院肿瘤科、中医科及介入科收治的行TACE治疗的122例原发性肝癌住院患者,对其病例资料进行回顾性分析,根据治疗方案将所有患者分为化学治疗组与中药联合组,化学治疗组男30例,女29例,年龄(59.4±9.6)岁,年龄范围为34~74岁。中药联合组男38例,女28例,年龄(60.8±8.4)岁,年龄范围为33~70岁。化学治疗组患者行TACE治疗,中药联合组患者在化学治疗组的基础上加用术后联合中药治疗,对治疗后两组患者的临床治疗效果及不良反应发生情况进行比较分析。结果中药联合组患者的部分缓解[71.4%(45/63)]与病变稳定[25.4%(16/63)]显著高于化学治疗组[64.4%(38/59)、23.7%(14/59)],差异有统计学意义(P<0.05),两组患者不良反应发生情况比较,差异无统计学意义(P>0.05)。结论中药联合TACE治疗能够提高治疗有效率,且不会增加不良反应发生率,可作为肝癌患者的治疗方案。
Objective To investigate the clinical efficacy of traditional Chinese medicine combined with transhepatic arterial chemotherapy and embolization(TACE)in the treatment of hepatocellular carcinoma(HCC). Methods A retrospective study was performed on 122 cases of patient with HCC who were treated with TACE from December 2013 to December 2018.According to the treatment plan, all patients were divided into the chemotherapy group and the combined group of traditional Chinese medicine.There were 59 cases in the chemotherapy group, including 30 male cases and 29 female cases.The age range was 34 to 74 years, aged(59.4±9.6)years.There were 63 patients in the combined group of traditional Chinese medicine, including 35 males and 28 females.The age range was 33 to 70 years, aged(60.8±8.4)years.Patients in the chemotherapy group were treated with TACE, and patients in the Chinese medicine combination group were treated with postoperative Chinese medicine combination on the basis of the chemotherapy group, and the clinical therapeutic effects and adverse reactions of the two groups were compared and analyzed. Results Partial remission[71.4%(45/63)] and lesion stability[25.4%(16/63)] of patients in the TCM combination group were significantly higher than those in the chemotherapy group[64.4%(38/59)and 23.7%(14/59)], with statistically significant differences(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion TACE combined with traditional Chinese medicine can improve the treatment efficiency, and does not increase the incidence of adverse reactions, which can be used as a treatment for liver cancer patients.
作者
刘永叶
韩涛
郑振东
Liu Yongye;Han Tao;Zheng Zhendong(Department of Oncology, the General Hospital of North Battlefield Tumor Center of PLA, Shenyang 110016, China)
出处
《中国临床实用医学》
2019年第2期10-13,共4页
China Clinical Practical Medicine
基金
辽宁省自然科学基金计划重点项目(20180530019).
关键词
肝癌
肝动脉化学治疗栓塞术
中药
Hepatocellular carcinoma
Transhepatic arterial chemotherapy and embolization
Traditional Chinese medicine
